Modelo de costos asociados al ataque cerebrovascular y los eventos adversos en pacientes con fibrilación auricular no valvular tratados con warfarina
Authors:
- José A. Mendoza-SánchezJMJosé A. Mendoza-Sánchez
- Federico A. SilvaFSFederico A. Silva
- Lady M. Rangel-CelisLRLady M. Rangel-Celis
- Jaime E. AriasJAJaime E. Arias
- Eduardo A. Zuñiga-SierraEZEduardo A. Zuñiga-Sierra
Open Access
- 1 May 2019
- journal article
- Published by Instituto Mexicano del Seguro Social in Revista Colombiana de Cardiología
- Vol. 26 (3) , 125-132
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial FibrillationCirculation, 2013
- Patterns of Warfarin Use in Subgroups of Patients with Atrial Fibrillation: A Cross-Sectional Analysis of 430 General Practices in the United KingdomPLOS ONE, 2013
- Warfarin therapeutic monitoring: is 70% time in the therapeutic range the best we can do?Journal of Clinical Pharmacy and Therapeutics, 2011
- Cost Efficiency of Anticoagulation With Warfarin to Prevent Stroke in Medicare Beneficiaries With Nonvalvular Atrial FibrillationStroke, 2011
- The Costs of Care in Atrial Fibrillation and the Effect of Treatment Modalities in GermanyValue in Health, 2009
- Principles of Good Practice for Budget Impact Analysis: Report of the ISPOR Task Force on Good Research Practices—Budget Impact AnalysisValue in Health, 2007
- An economic model of adverse events and costs for oral anticoagulants used for atrial fibrillationCurrent Medical Research and Opinion, 2007
- Major Bleeding Complications in a Specialized Anticoagulation ServiceThe American Journal of Cardiology, 2005
- Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patientsBMJ, 2004
- Carotid Endarterectomy RevisitedNew England Journal of Medicine, 2000